NCT Number: NCT00125892
A Study of Duloxetine in the Treatment of Fibromyalgia
This study is designed to evaluate duloxetine for the treatment of fibromyalgia syndrome patients.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday - Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Buenos Aires, Argentina
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Meet criteria for primary fibromyalgia syndrome as defined by the American College of Rheumatologists
Exclusion criteria
- Treatment with a monoamine oxidase inhibitor within 14 days prior to Visit 2 or the potential need to take within 5 days after discontinuation from the study.
- Any patients judged by their physicians to be at serious suicidal risk.
- Have uncontrolled narrow-angle glaucoma
Treatment and study plan
Primary outcomes
-
Evaluate safety and efficacy of duloxetine in patients diagnosed with fibromyalgia syndrome
Secondary outcomes
-
Evaluate persistence of efficacy
-
Evaluate long-term differences in efficacy in different doses
-
Evaluate gains in efficacy in non-responders
Sponsors and collaborators
Lead sponsor
Eli Lilly and Company
Industry
Collaborators
- Boehringer Ingelheim
Registry information
Official study title
A 1-Year Safety Study of Duloxetine in Patients With Fibromyalgia Syndrome
Important dates
- Study start
- 2005
- Study completion
- 2007
- First posted
- Aug 2, 2005
- Registry last updated
- May 17, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
The Clinical Impact of Integrated Behavioral Health Techniques in Patients With Fibromyalgia
NCT06988761
Fibromyalgia, Muscular Diseases
Rochester, Minnesota, United States
View Trial DetailsOrthorexia Nervosa in Fibromyalgia
NCT06947200
Fibromyalgia, Muscular Diseases
Istanbul, Turkey (Türkiye)
View Trial DetailsEffectiveness of AI-Guided Exercise and Pain Neuroscience Education for Fibromyalgia (FIBROIA)
NCT06672419
Fibromyalgia, Fibromyalgia Syndrome
Concepción, Biobio, Chile
View Trial DetailsFibromyalgia Syndrome in France: The Role of Assessment and Management of Sleep Disorders
NCT04775368
Fibromyalgia, Muscular Diseases
Amiens, France
View Trial Details